IGFBP5 Antikörper (AA 60-272)

Produktnummer ABIN5518921

Der Kaninchen Polyklonal Anti-IGFBP5-Antikörper wurde für WB und ELISA validiert. Er ist geeignet, IGFBP5 in Proben von Human zu detektieren. Es sind 4+ Publikationen verfügbar.

Kurzübersicht für IGFBP5 Antikörper (AA 60-272) (ABIN5518921)

Target: IGFBP5 (Insulin-Like Growth Factor Binding Protein 5 (IGFBP5))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IGFBP5 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Produktdetails anti-IGFBP5 Antikörper

Bindungsspezifität: AA 60-272

Verwendungszweck: Anti-IGFBP5 Antibody Picoband®

Kreuzreaktivität (Details): No cross-reactivity with other proteins.

Produktmerkmale: Anti-IGFBP5 Antibody Picoband® (ABIN5518921). Tested in ELISA, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Aufreinigung: Immunogen affinity purified.

Immunogen: E. coli-derived human IGFBP5 recombinant protein (Position: A60-E272). Human IGFBP5 shares 96.7% and 96.2% amino acid (aa) sequence identity with mouse and rat IGFBP5, respectively.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western blot, 0.1-0.5 μg/mL, Human
ELISA, 0.1-0.5 μg/mL, -
1. Allander SV, Larsson C, Ehrenborg E, Suwanichkul A, Weber G, Morris SL, Bajalica S, Kiefer MC, Luthman H, Powell DR (May 1994). "Characterization of the chromosomal gene and promoter for human insulin-like growth factor binding protein-5". J Biol Chem 269 (14): 10891-8. 2. Butt, A. J., Dickson, K. A., McDougall, F., Baxter, R. C. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J. Biol. Chem. 278: 29676-29685, 2003.

Kommentare:

We recommend Enhanced Chemiluminescent Kit with anti-Rabbit IgG (ABIN921124) for Western blot.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Konzentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

Referenzen für anti-IGFBP5 Antikörper (ABIN5518921)

Wan, Ma, Mei, Shan: "The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells." in: Journal of experimental & clinical cancer research : CR, Vol. 28, pp. 150, (2010) (PubMed).

Hou, Zhang, Liu, Meng, Qiao: "Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology." in: Journal of experimental & clinical cancer research : CR, Vol. 28, pp. 70, (2009) (PubMed).

Khullar, Sehgal: "Evaluation of CIEP and ELISA in a rodent malaria model." in: Indian journal of pathology & microbiology, Vol. 32, Issue 4, pp. 252-5, (1990) (PubMed).

Fruscella: "[Liposuction in plastic surgery]." in: Minerva ginecologica, Vol. 41, Issue 4, pp. 195-7, (1989) (PubMed).

Details zu IGFBP5

Target: IGFBP5 (Insulin-Like Growth Factor Binding Protein 5 (IGFBP5))

Andere Bezeichnung: IGFBP5

Hintergrund:

Synonyms: Insulin-like growth factor-binding protein 5,IBP-5,IGF-binding protein 5,IGFBP-5,IGFBP5,IBP5,

Tissue Specificity: Osteosarcoma, and at lower levels in liver, kidney and brain.

Background: Insulin-like growth factor-binding protein 5 is a protein that in humans is encoded by the IGFBP5 gene. The expression of IGFBP5 by stable transfection and adenovirus-mediated infection is inhibitory to growth in 2 human breast cancer cell lines. IGFBP5 expression leads to G2/M cell cycle arrest and apoptosis. Stable expression of IGFBP5 in the breast cancer cell lines also inhibits the formation and growth of tumors following injection in athymic mice. It is concluded that IGFBP5 is a growth inhibitor and proapoptotic agent in breast cancer cells. Additionally, IGFBP-5 is expressed by fibroblasts, myoblasts and osteoblasts, making it the predominant IGFBP found in bone extracts. It has a strong affinity for hydroxyapatite, allowing it to bind to bone cells. When bound to extracellular matrix, IGFBP-5 is protected from proteolysis and potentiates IGF activity, but when it is soluble, IGFBP-5 is cleaved to a biologically inactive 21 kDa fragment (1, 2).

Molekulargewicht: 31 kDa

Gen-ID: 3488

UniProt: P24593

Pathways: WNT Signalweg, Carbohydrate Homeostasis, Myometrial Relaxation and Contraction, Regulation of Carbohydrate Metabolic Process, Autophagie, Smooth Muscle Cell Migration, Growth Factor Binding